EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Platelet CLEC-2 activation leads to GPIb⍺ shedding: Implications for doxorubicin chemotherapy and thrombosis

Zackary Rousseau, Wenjing Ma, Tianle Long, Sladjana Slavkovic, Xin Qiu, Xiaomei Lao, Xun Grace Wu, Kaishiv Joshi, Yunqing Amelia Zhu, Guangheng Zhu, Kelsie L Thu, Heyu Ni

Journal of Biological Chemistry · 2026-06 · 302 (6) · 113074

DOI: 10.1016/j.jbc.2026.113074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-06. Verfasst von Zackary Rousseau und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine, LKSKI-Keenan …. Hauptthemen laut MEDLINE: Doxorubicin, Lectins, C-Type, Platelet Glycoprotein GPIb-IX Complex, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Canadian Blood Services, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox) is a potent first-line chemotherapeutic and widely administered against different types of cancer, but is associated with a myriad of side effects, including cancer/chemotherapy-associated thrombosis and drug-induced thrombocytopenia. Although we and others have reported Dox-induced platelet activation, the binding partner of Dox on platelets has not been previously explored. Here, we found human and mouse platelet aggregation triggered via C-type lectin-like receptor-2 (CLEC-2) was obstructed by Dox, but aggregation induced by classical agonists like ADP, collagen/collagen-related peptide, or thrombin receptor-activating peptide 6, was unaffected. By isothermal titration calorimetry, we detected a high binding affinity between Dox and recombinant CLEC-2 at 4.2 ± 2.4 nM. Interestingly, we found significant GPIb⍺ shedding from human and mouse platelet surfaces following Dox treatment. Consistently, GPIb⍺ shedding was recapitulated following anti-CLEC-2 monoclonal antibody treatment. Using Piceatannol to selectively inhibit CLEC-2 intracellular signaling or the pan-matrix metalloproteinases inhibitor GM6001 rescued glycoprotein Ibα (GPIbα) from both Dox and CLEC-2 mAb-induced shedding. Using GI254023X or GW280264X to specifically inhibit ADAM10 or ADAMs10/17, respectively, revealed inhibition of ADAM10/17, but not ADAM10 exclusively, prohibited GPIbα shedding. Collectively, this implicates the classical sheddase of GPIbα, ADAM17. Thus, we pinpointed CLEC-2 as a binding partner for Dox on platelets and a novel pathway of ADAM17-mediated GPIb⍺ shedding via CLEC-2. These data not only provide insights into a mechanism of Dox-induced platelet activation, thrombosis, and drug-induced thrombocytopenia, but also reveal putative precision therapeutic approaches for Dox-treated patients and nominate CLEC-2 inhibition as a means to regulate thrombotic disease and/or bleeding disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLectins, C-TypePlatelet Glycoprotein GPIb-IX ComplexThrombosisBlood PlateletsAntibiotics, AntineoplasticAnimalsHumansMicePlatelet AggregationPlatelet ActivationMice, Inbred C57BLMembrane Glycoproteins

Stichwörter der Autor:innen

ADAM17CLEC-2GPIbα sheddingdoxorubicinintegrin αIIbβ3plateletsthrombocytopeniathrombosis

Substanzen

DoxorubicinLectins, C-TypePlatelet Glycoprotein GPIb-IX ComplexCLEC2B protein, humanCLEC-2 protein, mouseAntibiotics, AntineoplasticMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine, LKSKI-Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto…
  • Department of Laboratory Medicine, LKSKI-Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada; Toronto Platelet Immunobiology Group, Toronto, Ontario, Canada.

Förderung

  • Canadian Institutes of Health Research
  • Canadian Blood Services
  • China Scholarship Council
  • University of Toronto Temerty Faculty of Medicine
  • Cancer Research Society
  • Hospital for Sick Children

Zitieren

APA

Rousseau, Z., Ma, W., Long, T., Slavkovic, S., Qiu, X., Lao, X., Wu, X. G., Joshi, K., Zhu, Y. A., Zhu, G., Thu, K. L., & Ni, H. (2026). Platelet CLEC-2 activation leads to GPIb⍺ shedding: Implications for doxorubicin chemotherapy and thrombosis. Journal of Biological Chemistry, 302(6), 113074. https://doi.org/10.1016/j.jbc.2026.113074

Vancouver

Rousseau Z, Ma W, Long T, Slavkovic S, Qiu X, Lao X, et al. Platelet CLEC-2 activation leads to GPIb⍺ shedding: Implications for doxorubicin chemotherapy and thrombosis. Journal of Biological Chemistry. 2026;302(6):113074. doi:10.1016/j.jbc.2026.113074

BibTeX
@article{Rousseau2026,
  author = {Rousseau, Zackary and Ma, Wenjing and Long, Tianle and Slavkovic, Sladjana and Qiu, Xin and Lao, Xiaomei and Wu, Xun Grace and Joshi, Kaishiv and Zhu, Yunqing Amelia and Zhu, Guangheng and Thu, Kelsie L and Ni, Heyu},
  title = {Platelet CLEC-2 activation leads to GPIb⍺ shedding: Implications for doxorubicin chemotherapy and thrombosis},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  volume = {302},
  number = {6},
  pages = {113074},
  doi = {10.1016/j.jbc.2026.113074}
}
Kostenlos starten →